[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-360011-105":59,"doc-detail-360011-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","real-world-treatment-patterns-in-patients-with-biochemical-recurrence-after-local-prostate-cancer-therapy","Real-world treatment patterns in patients with biochemical recurrence after local prostate cancer therapy","","Aim: The study describes real-world anticancer treatment patterns in the USA for prostate cancer patients who develop biochemical recurrence (BCR) after radical prostatectomy or radiation therapy, stratified by PSA doubling time. Methods: A retrospective observational cohort used Optum PC electronic medical records from 2012–2023, categorizing patients by PSA-DT (\u003C12 vs ≥12 months) and validating with a ≤9/>9-month sensitivity cutoff. Results: Among 2,981 post-prostatectomy and 697 post-radiation patients, high-risk BCR received treatments more often, with salvage RT and ADT predominating. Conclusions: Androgen-deprivation therapy remains standard care, while ADT plus androgen receptor pathway inhibitors is rarely used even in high-risk patients.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/real-world-treatment-patterns-in-patients-with-biochemical-recurrence-after-local-prostate-cancer-therapy/360011/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/real-world-treatment-patterns-in-patients-with-biochemical-recurrence-after-local-prostate-cancer-therapy/360011.png","ImageObject",300,407,{"name":92,"@type":93},"Bintang","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-27","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",11,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What patient groups were analyzed in this study?","Question",{"text":113,"@type":114},"Patients with biochemical recurrence after radical prostatectomy or radiation therapy were included and stratified by PSA doubling time, with a sensitivity analysis using a different risk cutoff.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How did high-risk and low-risk patients differ in treatment use?",{"text":118,"@type":114},"Treatment use was higher among high-risk BCR patients in both the radical prostatectomy and radiation cohorts, based on comparisons of percentages reported in the results.",{"name":120,"@type":111,"acceptedAnswer":121},"What treatment combination was least commonly selected, even for high-risk BCR?",{"text":122,"@type":114},"ADT combined with an androgen receptor pathway inhibitor was infrequently used, even among high-risk biochemical recurrence patients.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},360011,1790174499,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":44,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},962085564381,"https://ap-avatar.wpscdn.com/davatar_6f874abed73319feea01a86fa6f0fab8","FUTURE ONCOLOGY  \n2026, VOL. 22, NO. 11, 1301–1309  \n[https://doi.org/10.1080/14796694.2026.2651959](https://doi.org/10.1080/14796694.2026.2651959)  \nRESEARCH ARTICLE     \nReal-world treatment patterns in patients with biochemical recurrence after local prostate cancer therapy  \nRana R. McKay a, Nasreen Khanb, Neal D. Shore c, Guifang Chenb, Vlasta Hlebecd, Shankar Srinivasan band Daniel E. Spratt e  \naDepartment of Medical Oncology, University of California, San Diego, CA, USA; bBayer HealthCare Pharmaceuticals, Inc., Whippany, NJ, USA; cDepartment of Urology, START Carolinas Research Center, Myrtle Beach, SC, USA; dBayer Consumer Care AG, Basel, Switzerland; e University Hospitals Seidman Cancer Center, Cleveland, OH, USA  \nABSTRACT  \nAim: Describe real-world anticancer treatment patterns in the USA among patients with prostate cancer (PC) who experience biochemical recurrence (BCR) following radical prostatectomy (RP) or radiation therapy (RT), stratified by prostate-specific antigen doubling time (PSA-DT) .  \nMethods: Retrospective, observational cohort study using the Optum® PC electronic medical record database (2012–2023) . Patients with BCR were stratified into high-/low-risk groups based on PSA-DT of \u003C12/≥12 months. A sensitivity analysis defined risk status using a ≤9-/>9-month cutoff.  \nResults: The study included 2,981 patients with BCR in the RP cohort and 697 in the RT cohort. Median follow-up was 30.8 months (Q1–Q3: 18.1–50.8) . Any treatment use was higher among high-risk BCR patients (RP: 67.1% vs 54.9%; RT: 52.8% vs 28.7%) . After RP, most patients received salvage RT (high-risk: 41.3%; low-risk: 40.7%), followed by androgen-deprivation therapy (ADT) monotherapy (high-risk: 30.2%; low-risk: 22.8%) and ADT plus androgen receptor pathway inhibitor (ARPI) (high-risk: 11.9%; lowrisk: 3.7%) . After RT, ADT monotherapy (high-risk: 22.9%; low-risk: 12.3%) and ADT plus ARPI (high-risk: 16.5%; low-risk 4.9%) were most common. Sensitivity analyses showed similar results.  \nConclusions: These findings demonstrate that ADT remains the predominant standard of care, whereas ADT plus ARPI is infrequently used, even among high-risk BCR patients.  \nPLAIN LANGUAGE SUMMARY  \nHow men are treated when their prostate cancer returns after initial therapy  \nProstate cancer (PC) is the most common cancer diagnosed in men in the USA and was the second leading cause of death in 2023. Primary treatment options include radical prostatectomy and radiation therapy (RT); however, approximately 20–50% of patients will subsequently show rising prostatespecific antigen–a state known as biochemical recurrence (BCR) . Patients with BCR tend to have high risk of morbidity and mortality, with many patients going on to develop metastasis. Therefore, it is important to monitor patients for BCR, identify their risk for disease progression, and tailor treatments to optimize outcomes. In this study, we examined medical record data from a large, nationally representative US database to examine real-world treatment patterns in patients with PC who developed BCR after primary therapy. The findings of our analysis suggest that many patients with BCR are not being treated–even those considered at high risk for disease progression. Of the patients who were treated, most received salvage RT or androgen-deprivation therapy alone. Patients and caregivers should discuss available treatment options and weigh individual risks and benefits at the first sign of BCR in PC. The use of androgen-deprivation therapy combined with a second-generation androgen receptor inhibitor is infrequently selected for patients with high-risk BCR.  \nARTICLE HISTORY  \nReceived 24 October 2025 Accepted 24 March 2026  \nKEYWORDS  \nAndrogen receptor inhibitors; biochemical recurrence; radiation therapy; prostate cancer; real-world treatment patterns  \n1. Introduction  \nIn the USA, prostate cancer (PC) is the most common cancer in men (excluding skin cancer) [1] and represented 29% of all c","cbCaiaI88dGkxnq6","https://ap.wps.com/l/cbCaiaI88dGkxnq6","pdf",336265,"English","# Introduction\n## Study background and definitions of biochemical recurrence\n# Methods\n## Data source and patient stratification\n# Results\n## Treatment patterns after radical prostatectomy and radiation therapy\n## Sensitivity analyses\n# Conclusions","[{\"question\":\"What patient groups were analyzed in this study?\",\"answer\":\"Patients with biochemical recurrence after radical prostatectomy or radiation therapy were included and stratified by PSA doubling time, with a sensitivity analysis using a different risk cutoff.\"},{\"question\":\"How did high-risk and low-risk patients differ in treatment use?\",\"answer\":\"Treatment use was higher among high-risk BCR patients in both the radical prostatectomy and radiation cohorts, based on comparisons of percentages reported in the results.\"},{\"question\":\"What treatment combination was least commonly selected, even for high-risk BCR?\",\"answer\":\"ADT combined with an androgen receptor pathway inhibitor was infrequently used, even among high-risk biochemical recurrence patients.\"}]","Real-world treatment patterns in patients with biochemical recurrence after local prostate cancer therapy | PDF",1790138505,23,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/fad2aba1b9456ad23143028faf68761d.webp",983,1280,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4f5166d9b3e7391a439aa96c4ef6a8dc.webp",982,1278,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/57adbca2fcfc0482c0647ea440b02486.webp",981,1277,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d2524ee59dfdbe054b859f254ae95382.webp",980,1276]